What are the recommended dosing, indications, and precautions for ertapenem in adult patients?

Ertapenem: Dosing, Indications, and Precautions

Ertapenem is a once-daily carbapenem antibiotic dosed at 1 gram IV for adults (or 15 mg/kg twice daily, not exceeding 1 g/day, for children 3 months to 12 years), approved for moderate-to-severe community-acquired infections including complicated intra-abdominal infections, complicated skin/soft tissue infections, community-acquired pneumonia, complicated UTIs, and acute pelvic infections. 1

Dosing Regimens

Adults and Adolescents ≥13 Years

• Standard dose: 1 gram IV once daily 1
• Infusion time: 30 minutes 1
• Duration: Up to 14 days IV or 7 days IM 1
• IM administration: Reconstitute with 3.2 mL of 1% lidocaine HCl (without epinephrine); use within 1 hour 1

Pediatric Patients (3 Months to 12 Years)

• Dose: 15 mg/kg twice daily (maximum 1 g/day) 1
• For children ≥13 years, use adult dosing 1

Renal Impairment Adjustments

• CrCl >30 mL/min/1.73 m²: No adjustment needed 1
• CrCl ≤30 mL/min/1.73 m²: Reduce to 500 mg daily 1
• Hemodialysis: If dosed within 6 hours before dialysis, give supplementary 150 mg dose after the session 1
• No data available for pediatric patients with renal impairment or those on peritoneal dialysis/hemofiltration 1

Hepatic Impairment

No dose adjustment recommendations can be made due to insufficient data 1

Approved Indications

Treatment Indications (Adults and Pediatrics ≥3 Months)

1. Complicated Intra-Abdominal Infections

• Duration: 5-14 days 1
• Ertapenem is recommended as single-agent therapy for mild-to-moderate community-acquired intra-abdominal infections 2
• Guideline support: Preferred over anti-pseudomonal agents for community-acquired cases 2
• Caveat: The expert panel expresses concern that broad use may hasten carbapenem-resistant Enterobacteriaceae, Pseudomonas, and Acinetobacter 2

2. Complicated Skin and Skin Structure Infections (Including Diabetic Foot)

• Duration: 7-14 days (up to 28 days for diabetic foot infections) 1
• Important limitation: Not studied in diabetic foot infections with concomitant osteomyelitis 1

3. Community-Acquired Pneumonia

• Duration: 10-14 days (includes possible switch to oral therapy after ≥3 days parenteral therapy once clinical improvement demonstrated) 1
• Equivalent efficacy to ceftriaxone for CAP due to Enterobacteriaceae 3

4. Complicated Urinary Tract Infections (Including Pyelonephritis)

• Duration: 10-14 days 1

5. Acute Pelvic Infections

• Includes postpartum endomyometritis, septic abortion, post-surgical gynecologic infections
• Duration: 3-10 days 1

Prophylaxis Indication (Adults Only)

Surgical Site Infection Prevention in Elective Colorectal Surgery

• Dose: 1 gram IV single dose given 1 hour prior to surgical incision 1
• Evidence: Single-dose ertapenem significantly improves compliance with SAP guidelines (96.6% vs 64.9% with multi-dose regimens) without increasing SSI rates 4
• Preferred over meropenem/imipenem due to single administration and antimicrobial stewardship considerations 5

Antimicrobial Spectrum

Ertapenem provides broad coverage against:

• Gram-negative aerobes: E. coli, Klebsiella species, Proteus mirabilis, Enterobacter species 2
• Gram-positive aerobes: Streptococci (including penicillin-resistant S. pneumoniae), methicillin-sensitive S. aureus 2, 6
• Anaerobes: Bacteroides fragilis group, Clostridium species, Prevotella, Peptostreptococcus 2
• Extended-spectrum β-lactamase (ESBL) and AmpC-producing Enterobacteriaceae 7, 6, 8

Critical gaps in coverage:

• No activity against: Pseudomonas aeruginosa, Acinetobacter species, MRSA, enterococci 6, 8
• This distinguishes ertapenem from imipenem and meropenem 6

Key Precautions and Contraindications

Absolute Contraindications

• Known hypersensitivity to ertapenem or anaphylactic reactions to β-lactams 1
• For IM administration only: Hypersensitivity to amide-type local anesthetics (due to lidocaine diluent) 1

Serious Warnings

1. Seizures and CNS Adverse Events

• Seizures reported during treatment 1
• Incidence in RRT patients: 2.5% 9
• Higher risk with standard dosing in renal impairment—dose adjustment critical 9

2. Drug Interaction with Valproic Acid

• Co-administration reduces valproic acid serum concentrations, potentially increasing breakthrough seizure risk 1
• Recommendation: Generally avoid concomitant use; consider alternative antibiotics for patients with well-controlled seizures on valproic acid/divalproex 10, 1

3. Clostridioides difficile-Associated Diarrhea

• Ranges from mild diarrhea to fatal colitis 1
• Evaluate if diarrhea develops during or after treatment 1

4. Hypersensitivity Reactions

• Serious anaphylactic reactions reported with β-lactams 1
• Cross-reactivity possible in patients with penicillin allergy

5. Probenecid Interaction

• Inhibits renal excretion of ertapenem; co-administration not recommended 1

Administration Precautions

• Do NOT mix or co-infuse with other medications 1
• Do NOT use diluents containing dextrose (α-D-glucose) 1
• IM injection: Avoid inadvertent injection into blood vessels 1
• Use with needleless IV systems not recommended 1

Common Adverse Effects

Most frequent (≥5% in adults):

• Diarrhea (5.0-5.6%) 11
• Nausea (2.5-3.4%) 11
• Headache 1
• Infused vein complications (3.2-4.5%) 11
• Elevated ALT (8.3-8.8%) 11

Pediatric patients (≥5%):

• Diarrhea, vomiting, infusion site pain 1

Tolerability: Most adverse events mild-to-moderate; overall safety profile comparable to piperacillin-tazobactam and ceftriaxone 11

Clinical Considerations

When to Choose Ertapenem

• Mild-to-moderate community-acquired infections where anti-pseudomonal coverage is unnecessary 2
• ESBL-producing Enterobacteriaceae infections 5, 7
• Once-daily dosing advantageous for outpatient parenteral therapy 8
• Surgical prophylaxis in colorectal surgery (single-dose convenience) 4

When NOT to Use Ertapenem

• Suspected or confirmed Pseudomonas, Acinetobacter, MRSA, or enterococcal infections 6
• High-severity healthcare-associated infections requiring broader coverage 2
• Patients on valproic acid with well-controlled seizures (use alternatives) 10, 1
• Immediate hypersensitivity to β-lactams 1

Antimicrobial Stewardship Concerns

The guidelines express explicit concern that widespread ertapenem use may accelerate carbapenem resistance in Enterobacteriaceae, Pseudomonas, and Acinetobacter 2. Reserve for appropriate indications rather than routine empiric use. For ESBL infections, ertapenem may be preferred over imipenem/meropenem to preserve broader-spectrum carbapenems for severe infections 5, 12.

Special Populations

• Elderly: No dose adjustment based on age alone if renal function normal 11
• Pregnancy/Lactation: Safety not established; use only if clearly needed
• Renal replacement therapy: Efficacy demonstrated but seizure risk higher—monitor closely 9